

Preparation and Characterization of Ethosomes for Topical delivery of Aceclofenac

A. K. BARUPAL, VANDANA GUPTA AND SUMAN RAMTEKE*

School of Pharmaceutical Sciences, Rajiv Gandhi Technical University, Airport Bypass Road, Gandhi Nagar, Bhopal-462 036, India

Barupal, *et al.*: Ethosomes for Topical delivery of Aceclofenac

The aim of present study was to prepare and characterized ethosomes of aceclofenac which may deliver the drug to targeted site more efficiently than marketed gel preparation and also overcome the problems related with oral administration of drug. The formulations were prepared with varying the quantity of ethanol 10-50% (v/v), lecithin 1-4% (w/v), propylene glycol 5-20% (v/v) and evaluated for their vesicle size, shape and surface morphology, entrapment efficiency and *in vitro* drug permeation study. Ethosomes of average size of 1.112 μm with a spherical shape bearing smooth surface were observed by transmission electron microscopy and surface electron microscopy. The maximum entrapment of ethosomes was 91.06 \pm 0.79%. Cumulative amount of drug permeated through the biological membrane was found to be in the range of 0.26 \pm 0.014 to 0.49 \pm 0.032 mg/cm². Stability profile of prepared system was assessed for 45 days and the results revealed that very less degradation of drug was observed during storage condition.

Key words: Aceclofenac, ethosomes, topical delivery, soya lecithin

Antiinflammatory drugs are a heterogeneous group with differing chemical and physical properties. The first choice of treatment for most patients is non steroidal antiinflammatory drugs (NSAIDs)^[1], aceclofenac is one of them, mainly used for the treatment of rheumatoid arthritis and osteoarthritis^[2]. In some comparative studies of joint diseases, there was a tendency for aceclofenac to be better tolerated than diclofenac or ketoprofen with fewer patients being withdrawn from treatment due to gastric intolerance^[3]. The patient treated with oral administration of aceclofenac suffers from various side effects, such as gastrointestinal ulcer and anemia due to gastrointestinal bleeding. Transdermal application of aceclofenac, as an alternative route of administration has demonstrated better to sort-out these problems, and it was speculated that topical administration of aceclofenac may increase the patient compliance and a possibility for continuous transdermal absorption of drug in controlled manner^[4]. Currently, no drug delivery system is available as ideal to attain all the desired goals, but sincere efforts can be made to accomplish them through novel strategies in drug delivery.

Apart from this numbers of novel drug delivery systems have been reported for various routes of administration, to achieve local and systemic drug delivery in controlled manner, whereas lipidic vesicular drug delivery systems such as liposomes, niosomes, transfersoms, and pharmacosomes were also developed for topical/transdermal administration of drug molecules^[5].

The vesicular approach i.e. liposome in transdermal drug delivery system has been studied for many purposes but the unstable nature limits their use at clinical and industrial levels. In order to increase the stability of liposomes concept of proliposomes has been proposed. But because of poor skin permeability, breaking of vesicles, leakage of drug, aggregation and fusion of vesicles, these systems are not much successful for effective transdermal drug delivery^[6].

Recently an innovative flexible vesicular system, ethosomes has been developed for topical/transdermal delivery of a drug. This system has wonderful property to permeate intact through the human skin due to its high elasticity properties, which has an immense consequence for design of

*Address for correspondence

E-mail: sapna1731@rediffmail.com

carrier system to be applied topically both for local and systemic delivery of hydrophilic and lipophilic drugs^[7].

Dayan and Touitou (2000) compared the ethosomal system and classic liposomal system of trihexyphenidyl HCl and found that ethosomes dramatically enhanced the skin permeation of trihexyphenidyl HCl *in vitro*^[8]. Further transdermal delivery system for cannabidiol by using ethosomal carrier was also designed by Lodzki and colleagues (2003)^[9]. Again Godin and Touitou (2004) investigated the dermal and intracellular delivery of bacitracin from ethosomes^[10]. After that Elsayed *et al.* (2006) studied the mechanism by which ethosomes can improve skin delivery of ketotifen under non-occlusive conditions^[11,12].

MATERIALS AND METHODS

Soya lecithin was purchased from Acros Organics, New Delhi, India. Aceclofenac was obtained as gift sample from Alembic Ltd., Vadodara, India. Triton-X 100 was purchased from Himedia Laboratories Pvt. Ltd. Mumbai, India. Methanol, propylene glycol and ethanol were purchased from Merck India Ltd. Mumbai, India.

Preparation of ethosomes containing aceclofenac:

Ethosomes were prepared as reported by Touitou *et al.* (2000)^[13]. In brief the lecithin (1-4% w/v) was taken in a small round bottom flask and solubilized with ethanol (10-50% v/v) containing drug under mixing with a magnetic stirrer. The round bottom flask was covered to avoid ethanol evaporation. Distilled water was added slowly with continuous stirring to obtain the ethosomal colloidal suspensions. The final suspension of ethosomes was kept at room temperature for 30 min under continuous stirring. Formulations were stored in the refrigerator and evaluated for vesicle size, vesicular shape, surface morphology, entrapment efficiency, *in vitro* drug permeation study and stability study.

Vesicle size and surface morphology:

Size and size distribution were determined by dynamic light scattering (DLS) using a computerized inspection system (Malvern Zetamaster ZEM 5002, Malvern, UK). Surface morphology was determined by TEM, for TEM a drop of the sample was placed on a carbon-coated copper grid and after 15 min it

was negatively stained with 1% aqueous solution of phosphotungstic acid. The grid was allowed to air dry thoroughly and samples were viewed on a transmission electron microscopy (TEM, FEI-Philips Tecnai 10). Scanning electron microscopy (SEM) was also conducted to characterize the surface morphology of the ethosomal vesicles for which a drop of ethosomal system was mounted on clear glass stub, air dried and coated with Polaron E 5100 Sputter coater (Polaron, UK) and visualized under Scanning Electron Microscope (SEM Leo 430, England).

Entrapment efficiency:

Aliquots of ethosomal dispersion were subjected to centrifugation using cooling ultracentrifuge (Remi) at 12000 rpm. The clear supernatant was siphoned off carefully to separate the untrapped aceclofenac and the absorbance was recorded at λ_{max} 277 nm using UV/Vis spectrophotometer (Shimadzu UV 1700). Sediment was treated with 1 ml of 0.1% Triton X 100 to lyse the vesicles and then diluted to 100 ml with methanol and absorbance was taken at 277 nm. Amount of aceclofenac in supernatant and sediment gave a total amount of aceclofenac in 1 ml dispersion. The percent entrapment was calculated using the formula, % entrapment = amount of aceclofenac in sediment/amount of aceclofenac added $\times 100$

In vitro drug permeation study:

The *in vitro* permeation study was carried out by using modified Franz diffusion cell with egg membrane. The study was performed with phosphate buffer saline (pH 7.4). The formulation was placed (equivalent to 2.5 mg of drug) on the upper side of skin in donor compartment. The temperature of the assembly was maintained at $37 \pm 2^\circ$. Samples were withdrawn after every hour from the receptor media through the sampling tube and at the same time, same amount of fresh receptor media was added to make sink condition. Withdrawn samples were analyzed for aceclofenac constant using UV/Vis spectrophotometer.

Stability study:

Optimized ethosomal formulations were selected for stability study. Formulations were stored at $4 \pm 2^\circ$, 8° and at room temperature. Percent drug entrapment was determined at different time intervals (1, 15, 30 and 45 d).

RESULTS AND DISCUSSION

In the present work, ethosomal formulation to enhance transdermal permeation of aceclofenac, was prepared and evaluated. Colloidal suspensions of ethosomes were prepared by reported method. Ethosomal system was found to be easy to prepare and composed mainly of phospholipids and ethanol, compounds commonly found in pharmaceutical preparations.

The average vesicle size of optimized formulations determined by Malvern Zetamaster was $1.112 \pm 0.053 \mu\text{m}$. TEM photographs showed the surface morphology of the ethosomes as well as existence of unilamellar vesicular structure (fig. 1). The smooth surface of vesicles was confirmed by SEM (fig. 2).




Fig. 1: Transmission electron microphotograph
Visualization of ethosomes by transmission electron microscopy ($\times 8400$)



Fig. 2: Scanning electron microphotograph
Visualization of ethosomes by scanning electron microscopy (bar $2 \mu\text{m}$)

The entrapment efficiency of ethosomes was determined for all formulations. Effect of ethanol concentration was observed on percent drug entrapment of ethosomes. The maximum entrapment efficiency was found to be $91.06 \pm 0.79\%$ for formulation ETE3 and minimum $53.36 \pm 0.82\%$ for formulation ETE5, respectively. There was increase in percent drug entrapment was observed with an increase in ethanol concentration, but when ethanol concentration exceeded 30%, a decrease in percent drug entrapment was observed. Improvement in aqueous solubility of aceclofenac was achieved with higher concentration of ethanol, which could be due to its co-solvent effect. Therefore, the more drug amount could be accommodated in the aqueous core of the vesicles however, as the concentration of ethanol increased above 30% resulting into leakage of drug from fluidized bilayer of vesicles.

The entrapment efficiency also increased with an increase in concentration of lecithin but, after 3 % of lecithin concentration there was no significant increase in percent entrapment was observed. The minimum percent entrapment observed for formulation ETL1 was $77.03 \pm 0.80\%$ and maximum for formulation ETL4 was $91.21 \pm 0.80\%$, respectively. This may be due to the lipophilic nature of drug which could get more encapsulated in lipid bilayer of the formulation (Table 1).

Increase in propylene glycol concentration decreases the entrapment of drug in formulations. Percent entrapment of ETP1 and ETP4 formulations was found to be $90.11 \pm 0.1\%$ and $68.31 \pm 0.90\%$, respectively. The results revealed that as the concentration of permeation enhancer increased, the fluidity of bilayer also increased causing the drug to leach out from vesicles.

The effect of ethanol, lecithin and propylene glycol on drug permeation rate of aceclofenac was studied. On increasing the amount of ethanol from 10-0.30%, drug permeation was found to be increased where as further increase in ethanol concentration the drug permeation was found to be decreased which could be due to the disruption of bilayer vesicles at higher concentration of ethanol. The maximum permeation was found to be $0.41 \pm 0.080 \text{ mg/cm}^2$ at 30% ethanol concentration (fig. 3).

As the lecithin is the main component of ethosomal

system play important role in formulation. In present study the effect of lecithin concentration on drug permeation was also evaluated to optimize the formulation for sustained release properties on system. In prepared ethosomal system, as the concentration of lecithin increased above 2%, permeation of drug decreased from 0.42 ± 0.022 mg/cm² due to decrease in the bilayer deformability of vesicles (fig. 4).

Variation in propylene glycol concentration also influenced the amount of drug permeated. The cumulative amount of drug permeated was maximum (formulation ETP2) 0.49 ± 0.032 mg/cm² and minimum

for (formulation ETP4) 0.27 ± 0.080 mg/cm² (fig. 5), due to propylene glycol shows synergistic effect with ethanol but above 10 % there is disruption of vesicles.

The cumulative amount permeated from optimized ethosomal system (ETP2) and Movon Gel after 24 h was 0.49 ± 0.032 mg/cm², 0.31 ± 0.036 mg/cm², respectively (fig. 6). A significant increase in amount permeated from ethosomal system was observed as compared to marketed formulation which could be due to sustained release behavior of system.

The optimized formulation was selected for stability study of vesicles at different temperatures. All

TABLE 1: ETHOSOMAL FORMULATIONS WITH DIFFERENT CONCENTRATION

Formulation code	Lecithin concentration (%)	Propylene glycol concentration (%)	Ethanol concentration (%)
ETE1	3	-	10
ETE2	3	-	20
ETE3	3	-	30
ETE4	3	-	40
ETE5	3	-	50
ETL1	1	-	30
ETL2	2	-	30
ETL3	3	-	30
ETL4	4	-	30
ETP1	2	5	30
ETP2	2	10	30
ETP3	2	15	30
ETP4	2	20	30

TABLE 2: ENTRAPMENT EFFICIENCY AND CUMULATIVE AMOUNT OF DRUG PERMEATED AFTER 24 h

Formulation code	Entrapment	Cumulative amount of drug permeated (mg/cm ²)
ETE1	84.59±0.86	0.30±0.010
ETE2	87.45±0.81	0.38±0.012
ETE3	91.06±0.79	0.41±0.080
ETE4	62.31±0.84	0.35±0.022
ETE5	53.36±0.82	0.26±0.014
ETL1	77.03±0.80	0.32±0.067
ETL2	90.01±0.92	0.42±0.022
ETL3	91.06±0.88	0.41±0.014
ETL4	91.21±0.79	0.33±0.036
ETP1	90.11±1.01	0.45±0.054
ETP2	89.86±0.85	0.49±0.032
ETP3	81.65±0.93	0.32±0.073
ETP4	68.31±0.90	0.27±0.080

TABLE 3: STABILITY OF VESICLES ON STORAGE

Time (d)	Entrapment (%)			
	4±2°	8±2°	37±2°	Room temperature
1	89.86±0.85	89.86±0.85	89.86±0.85	89.86±0.85
15	89.82±0.76	89.73±0.73	88.88±0.71	88.78±0.75
30	89.53±0.92	88.58±0.90	87.07±0.85	87.67±0.86
45	88.97±0.83	88.29±0.82	87.89±0.89	86.89±0.89




Fig. 3: Ethanol effect on *in vitro* drug permeation profile
Effect of ethanol concentration on *in vitro* cumulative drug permeation from various formulations, ETE1 (—◆—), ETE2 (—■—), ETE3 (—▲—), ETE4 (—○—) and ETE5 (—*—)




Fig. 4: Lecithin effect on *in vitro* drug permeation profile
Effect of lecithin concentration on *in vitro* cumulative amount of drug permeation from various formulations ETL1 (—▲—), ETL2 (—◆—), ETL3 (—△—) and ETL4 (—■—)




Fig. 5: Propylene glycol effect on *in vitro* drug permeation profile. Effect of propylene glycol concentration on *in vitro* cumulative amount of drug permeation from various formulations ETP1 (—◇—), ETP2 (—■—), ETP3 (—○—) and ETP4 (—▲—)




Fig. 6: *In vitro* drug permeation profile of optimized ethosomal formulation. *In vitro* permeation study of optimized ethosomal formulation ETP2 (—◇—) and comparison with marketed preparation Movon gel (—●—)

formulations were stored in amber glass container at different temperature. The drug content after treatment with triton X100 and % residue of aceclofenac was calculated as given in Table 3. Only $2 \pm 1\%$ degradation was observed at $37 \pm 2^\circ$, at room temperature only 3% degradation was observed however all formulations were almost stable at $8 \pm 2^\circ$ and $4 \pm 2^\circ$ and only $1.57 \pm 0.2\%$ degradation of aceclofenac was observed showed that developed system is stable at low temperature.

These flexible vesicles may become a promising carrier for the transdermal delivery of aceclofenac. It helps in reducing the dose of drug applied topically. The data presented here suggest the possibility of substituting systemic treatment of osteoarthritis and rheumatoid arthritis with local treatment. This would result in decreased gastrointestinal associated side-effects, thereby potentially increasing patient compliance.

ACKNOWLEDGEMENTS

Authors would like to express sincere gratitude towards Prof. Shashi Wadhwa, officer in charge AIIMS, New Delhi, India; Dr. N. C. Mehrotra, Director, Birbal Sahni Institute of Palaeobotany, Lucknow, India, for providing SEM, TEM facility and Dr. M. N. V. Ravikumar Center for Pharmaceutical Nanotechnology NIPER, Chandigarh, India for providing particle size analysis.

REFERENCES

1. Jason DM, Jackson R. Analgesic, antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman

- JG, Limbird LE, Gilman AG, editors. The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw Hill: 2001. p. 711-9.
2. Yamazaki R, Kawai S, Matsuzaki T, Kaneda N, Hashimoto S, Yokokura T, *et al.* Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. *Eur J Pharmacol* 1997;329:181-7.
3. Pasero G, Marcolongo R, Serni U, Parnham MJ, Ferrer F. A multicentre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. *Curr Med Res Opin* 1995;13:305.
4. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. *Drugs* 2000;60:555-74.
5. Schreir H, Bouwstra J. Liposome and niosomes as topical drug carriers, dermal and transdermal drug delivery. *J Control Release* 1994;30:1-15.
6. Cevc G, Blume G, Schatzlein A. *In vivo* Transfersomes mediated transepidermal delivery improves regiospecificity and biological activity of corticosteroids. *J Control Release* 1997;45:211-26.
7. Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: *In vitro* percutaneous permeation through human skin and *in vivo* anti-inflammatory activity on human volunteers. *J Control Release* 2005;106:99-110.
8. Dayan N, Touitou E. Carriers for skin delivery of trihexyphenidyl HCl: Ethosomes vs. liposomes. *Biomaterials* 2000;21:1879-85.
9. Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. *J Control Release* 2003;93:377-87.
10. Godin B, Touitou E. Mechanism of bacitracin permeation enhancement through the skin and cellular membranes from an ethosomal carrier. *J Control Release* 2004;94:365-79.
11. Elsayed MM, Abdallah OY, Naggat VF, Khalafallah NM. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. *Int J Pharm* 2006;322:60-6.
12. Touitou E, Godin B, Dayan N, Weiss C, Pilipovsky A, Levi-Schaffer F. Intracellular delivery mediated by an ethosomal carrier. *Biomaterials* 2001;22:3053-9.
13. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. *J Control Release* 2000;65:403-18.

Accepted 14 September 2010

Revised 20 August 2010

Received 1 September 2009

Indian J. Pharm. Sci., 2010, 72 (5): 582-586